Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13569335 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNACTSSCTSLHTT | |
| SCHEMBL13570108 | 0.93 | KLK1 (0.49) | SMN1; SMN2LMNACTSSCTSLHTT | |
| SCHEMBL4254215 | 0.93 | KLK1 (0.49) | SMN1; SMN2LMNACTSSCTSLHTT | |
| SCHEMBL13569338 | 0.93 | KLK1 (0.49) | SMN1; SMN2LMNACTSSCTSLHTT | |
| SCHEMBL13569340 | 0.92 | LMNA (0.48) | SMN1; SMN2LMNACTSSCTSLHTT | |
| SCHEMBL13569337 | 0.92 | LMNA (0.48) | SMN1; SMN2LMNACTSSCTSLHTT | |
| SCHEMBL4258226 | 0.91 | CA1 (0.57) | SMN1; SMN2LMNACTSSCTSLHTT | |
| SCHEMBL13570167 | 0.91 | CA1 (0.57) | SMN1; SMN2LMNACTSSCTSLHTT | |
| SCHEMBL13570187 | 0.88 | CA1 (0.46) | SMN1; SMN2LMNACTSSCTSLHTT | |
| SCHEMBL4252255 | 0.88 | CA1 (0.46) | SMN1; SMN2LMNACTSSCTSLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632972-B2 | Reacting an acid and an amine; apoptosis; carbamate, and N-phenethyl-2-phenylacetamide | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLIONIS (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632972-B2 | Reacting an acid and an amine; apoptosis; carbamate, and N-phenethyl-2-phenylacetamide | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLIONIS (US) | 2009-12-15 | — | — | US | disclosed |
| US-20050197511-A1 | Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells | NATIONAL SCIENCE FOUNDATION | 2005-09-08 | — | — | US | disclosed |
| WO-2005044191-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CANCER AND MODULATION OF PROGRAMMED CELL DEATH FOR MELANOMA AND OTHER CANCER CELLS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197511-A1 | Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells | BAD, MCL1, CASP3 | SMN1; SMN2 2432/4885LMNA 1958/4885CTSS 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.